Complications of corneal collagen cross-linking

Corneal collagen cross-linking (CXL) is an effective treatment for arresting progression in patients with keratoconus. CXL was approved by United States Food and Drug Administration for the treatment of progressive keratoconus in 2016. It is a relatively safe procedure with a low complication rate....

Descripción completa

Detalles Bibliográficos
Autores principales: Agarwal, Richa, Jain, Parul, Arora, Ritu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333012/
https://www.ncbi.nlm.nih.gov/pubmed/35502012
http://dx.doi.org/10.4103/ijo.IJO_1595_21
_version_ 1784758787519807488
author Agarwal, Richa
Jain, Parul
Arora, Ritu
author_facet Agarwal, Richa
Jain, Parul
Arora, Ritu
author_sort Agarwal, Richa
collection PubMed
description Corneal collagen cross-linking (CXL) is an effective treatment for arresting progression in patients with keratoconus. CXL was approved by United States Food and Drug Administration for the treatment of progressive keratoconus in 2016. It is a relatively safe procedure with a low complication rate. As this approach becomes more popular, it is paramount to be familiar with the potential complications associated with the procedure and its management. This article aims to report and review the complications of CXL for the treatment of keratoconus and post-LASIK ectasia.
format Online
Article
Text
id pubmed-9333012
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-93330122022-07-29 Complications of corneal collagen cross-linking Agarwal, Richa Jain, Parul Arora, Ritu Indian J Ophthalmol Review Article Corneal collagen cross-linking (CXL) is an effective treatment for arresting progression in patients with keratoconus. CXL was approved by United States Food and Drug Administration for the treatment of progressive keratoconus in 2016. It is a relatively safe procedure with a low complication rate. As this approach becomes more popular, it is paramount to be familiar with the potential complications associated with the procedure and its management. This article aims to report and review the complications of CXL for the treatment of keratoconus and post-LASIK ectasia. Wolters Kluwer - Medknow 2022-05 2022-04-28 /pmc/articles/PMC9333012/ /pubmed/35502012 http://dx.doi.org/10.4103/ijo.IJO_1595_21 Text en Copyright: © 2022 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Agarwal, Richa
Jain, Parul
Arora, Ritu
Complications of corneal collagen cross-linking
title Complications of corneal collagen cross-linking
title_full Complications of corneal collagen cross-linking
title_fullStr Complications of corneal collagen cross-linking
title_full_unstemmed Complications of corneal collagen cross-linking
title_short Complications of corneal collagen cross-linking
title_sort complications of corneal collagen cross-linking
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333012/
https://www.ncbi.nlm.nih.gov/pubmed/35502012
http://dx.doi.org/10.4103/ijo.IJO_1595_21
work_keys_str_mv AT agarwalricha complicationsofcornealcollagencrosslinking
AT jainparul complicationsofcornealcollagencrosslinking
AT aroraritu complicationsofcornealcollagencrosslinking

Ejemplares similares